These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use. Melander A; Bitzén PO; Faber O; Groop L Drugs; 1989 Jan; 37(1):58-72. PubMed ID: 2651086 [TBL] [Abstract][Full Text] [Related]
6. Drug-induced disorders of glucose metabolism. Mechanisms and management. Chan JC; Cockram CS; Critchley JA Drug Saf; 1996 Aug; 15(2):135-57. PubMed ID: 8884164 [TBL] [Abstract][Full Text] [Related]
7. The use of sulphonylureas in the elderly. Graal MB; Wolffenbuttel BH Drugs Aging; 1999 Dec; 15(6):471-81. PubMed ID: 10641958 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Harrower AD Clin Pharmacokinet; 1996 Aug; 31(2):111-9. PubMed ID: 8853933 [TBL] [Abstract][Full Text] [Related]
9. Comparative tolerability of sulphonylureas in diabetes mellitus. Harrower AD Drug Saf; 2000 Apr; 22(4):313-20. PubMed ID: 10789825 [TBL] [Abstract][Full Text] [Related]
10. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic optimisation of oral hypoglycaemic therapy. Marchetti P; Giannarelli R; di Carlo A; Navalesi R Clin Pharmacokinet; 1991 Oct; 21(4):308-17. PubMed ID: 1760902 [TBL] [Abstract][Full Text] [Related]
12. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Krentz AJ; Bailey CJ Drugs; 2005; 65(3):385-411. PubMed ID: 15669880 [TBL] [Abstract][Full Text] [Related]
13. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Langtry HD; Balfour JA Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345 [TBL] [Abstract][Full Text] [Related]
14. Sulphonylureas and cardiovascular disease: a problem for few diabetics. Slater SD; Ireland JT Scott Med J; 1979 Jan; 24(1):17-20. PubMed ID: 493926 [TBL] [Abstract][Full Text] [Related]
16. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. van Dalem J; Brouwers MC; Stehouwer CD; Krings A; Leufkens HG; Driessen JH; de Vries F; Burden AM BMJ; 2016 Jul; 354():i3625. PubMed ID: 27413017 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Marchetti P; Navalesi R Clin Pharmacokinet; 1989 Feb; 16(2):100-28. PubMed ID: 2656043 [TBL] [Abstract][Full Text] [Related]
18. Glipizide: a review of its pharmacological properties and therapeutic use. Brogden RN; Heel RC; Pakes GE; Speight TM; Avery GS Drugs; 1979 Nov; 18(5):329-53. PubMed ID: 389600 [TBL] [Abstract][Full Text] [Related]
19. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Scheen AJ Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007 [TBL] [Abstract][Full Text] [Related]
20. The role of sulphonylureas in the management of type 2 diabetes mellitus. Rendell M Drugs; 2004; 64(12):1339-58. PubMed ID: 15200348 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]